利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

165 records (took 0.015 seconds)

    WEIGHT MANAGEMENT COMPOSITION
    2.
    发明申请
    WEIGHT MANAGEMENT COMPOSITION 审中-公开

    公开(公告)号：WO2019178689A1

    公开(公告)日：2019-09-26

    申请号：PCT/CA2019/050342

    申请日：2019-03-20

    Applicant: EXERKINE CORPORATION

    Inventor： TARNOPOLSKY, Mark

    IPC: A61K36/82 ,  A61K31/122 ,  A61K31/353 ,  A61K31/355 ,  A61K31/385 ,  A61K36/36 ,  A61K36/74 ,  A61P3/04 ,  C07C50/28 ,  C07D311/78 ,  C07D339/04

    Abstract: A method for promoting weight management in a mammal is provided, comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondria enhancing agent. The weight loss agent may be selected from the group consisting of psyllium, guar gum, capsaicin, chitosan, caffeine, garcinia cambogia, Pinus densiflora, capsaicin, yohimbre, hoodia, glucomannan, African mango, guarana, pyruvate, carnitine, beta-glucan, fucoxanthin, raspberry ketone, white kidney bean, kola nut, chromium, ginseng, psyllium, St. John's wort, dandelion, hydroxycitric acid, conjugated linoleic acid, green tea, black tea, green coffee beans extract, forskolin and bitter orange. The mitochondria enhancing agent may be selected from the group consisting of beetroot extract, nitrate, idebenone, nicotinamide riboside, elamepratide, vitamin C, vitamin D, vitamin E, thiamine, riboflavin, magnesium, calcium, phosphate, phospholipid, creatine, pyruvate, coenzyme Q10, NADH, nicotinic acid, L-camitine, dicholoracetate, curcumin, schisandrin and resveratrol. Compositions for weight management are also provided.

    COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
    3.
    发明申请
    COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF 审中-公开

    公开(公告)号：WO2019150341A1

    公开(公告)日：2019-08-08

    申请号：PCT/IB2019/050901

    申请日：2019-02-05

    Applicant: CELLIXBIO PRIVATE LIMITED

    Inventor： KANDULA, Mahesh

    IPC: A61K31/4178 ,  A61K9/00 ,  C07D339/04

    Abstract: The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof. The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid.

    1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS
    4.
    发明申请
    1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS 审中-公开
    1,2-二硫杂环戊烷化合物用于神经保护，自身免疫和癌症疾病和病症

    公开(公告)号：WO2018049127A1

    公开(公告)日：2018-03-15

    申请号：PCT/US2017/050634

    申请日：2017-09-08

    Applicant: SABILA BIOSCIENCES LLC

    Inventor： MANSOUR, Tarek, S. ,  EVANS, Collen, E.

    IPC: A61K31/519 ,  A61K31/4162 ,  C07D339/04

    Abstract: This invention provides confounds of the formula (I): wherein Y 1 , Y 2 Z, X 1 , X 2 , and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor signaling pathway kinases-mediated diseases; or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3 -ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROSI; MAPK pathway kinases selected from ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, and MEK7; and P13K/AKT/mTor pathway kinases: selected from mTor, P13K a, Ρ13Κ β, P13Kγ, and P13K δ.

    Abstract translation: 本发明提供了式（I）的混淆：其中Y 1，Y 2 Z，X 1， ，X 2，W和W在说明书中定义。 这些化合物可用于治疗酪氨酸激酶，MAPK信号传导途径激酶和PI3K / AKT / mTor信号传导途径激酶介导的疾病; 或条件，如神经变性，神经保护，癌症，自身免疫以及与调节选自FYN，FYN Y531F，FLT3，FLT3-ITD，BRK，ITK，FRK，BTK，BMX，SRC的酪氨酸激酶有关的其他疾病和病症 ，FGR，YES1，LCK，HCK，RET，CSK，LYN和ROSI; 选自ARAF，BRAE CRAP，ERK1 / 2，MEK1，MEK2，MEK3，MEK4，MEK5的MAPK途径激酶。 MEK6和MEK7; 和P13K / AKT / mTor途径激酶：选自mTor，P13Ka，P13Kβ，P13Kγ和P13Kδ。

    IMPROVED PROCESS FOR THE SYNTHESIS OF 2, 6-XYLIDINE AND ITS DERIVATIVES
    5.
    发明申请
    IMPROVED PROCESS FOR THE SYNTHESIS OF 2, 6-XYLIDINE AND ITS DERIVATIVES 审中-公开
    改进的合成2,6-木二糖及其衍生物的方法

    公开(公告)号：WO2017085733A2

    公开(公告)日：2017-05-26

    申请号：PCT/IN2016/000266

    申请日：2016-11-09

    Applicant: KRISANI BIOSCIENCES (P) LTD.

    Inventor： AKELLA SATYA SURYA VISWESWARA SRINIVAS ,  KALIDINDI KRISHNAM RAJU

    IPC: C07D339/04 ,  A61K31/385 ,  A61P25/02

    CPC classification number: C07D339/04

    Abstract: The disclosure herein provides a composition of compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1 and its improved processes. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used for treatment of pain. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for noninvasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound of formula 1 may also be offered as a kit.

    Abstract translation: 本文的公开内容提供了式1化合物的组合物。本公开还提供了合成式1化合物及其改进方法的方法。 式1的化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物和水合物可以配制成用于治疗疼痛的药物组合物。 式1化合物或最终化合物的药物组合物可以配制用于非侵入性经口，局部（实例透皮），肠内，透粘膜，靶向递送，缓释递送，延迟释放，脉冲释放和肠胃外方法。 这种组合物可用于治疗表现为慢性疾病或其相关并发症的慢性疼痛。 式1的化合物也可以作为试剂盒提供。

    PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH
    6.
    发明申请
    PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH 审中-公开
    青霉胺及其衍生物用于治疗铜毒和NASH

    公开(公告)号：WO2017060914A3

    公开(公告)日：2017-05-18

    申请号：PCT/IN2016000231

    申请日：2016-09-21

    Applicant: KRISANI BIOSCIENCES (P) LTD

    Inventor： AKELLA SATYA SURYA VISWESWARA SRINIVAS ,  KALIDINDI KRISHNAM RAJU

    IPC: C07D339/04 ,  A61K31/385 ,  A61K31/427 ,  A61P1/16 ,  A61P39/04 ,  C07D277/06 ,  C07D417/12

    CPC classification number: C07D339/04 ,  C07D277/06 ,  C07D417/12

    Abstract: Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated as per oral, - topical, org.epo.ftm.SubType@4542e4b7[content={-}]. transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions can be used for the treatment of hepatic and genetic disorders related to copper toxicity, NASH and Leigh Syndrome.

    Abstract translation: 公开了青霉胺及其衍生物，组合物，合成和使用式1化合物的方法。 式1的化合物还包含其盐，多晶型物，溶剂化物和水合物。 这些化合物可以配制成药物组合物。 药物组合物可以按照口服，局部，org.epo.ftm.SubType@4542e4b7 [含量= { - }]配制。 透粘膜，吸入，靶向递送和持续释放制剂。 这种组合物可以用于治疗与铜毒性，NASH和Leigh综合征相关的肝和遗传病。

    PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH
    7.
    发明申请
    PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH 审中-公开
    苯胺胺及其衍生物用于治疗铜毒性和NASH

    公开(公告)号：WO2017060914A2

    公开(公告)日：2017-04-13

    申请号：PCT/IN2016/000231

    申请日：2016-09-21

    Applicant: KRISANI BIOSCIENCES (P) LTD.

    Inventor： AKELLA, Satya Surya Visweswara Srinivas ,  KALIDINDI, Krishnam Raju

    IPC: C07D339/04 ,  C07D417/12 ,  C07D277/06 ,  A61K31/427 ,  A61K31/385 ,  A61P39/04 ,  A61P1/16

    CPC classification number: C07D339/04 ,  C07D277/06 ,  C07D417/12

    Abstract: Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated as per oral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions can be used for the treatment of hepatic and genetic disorders related to copper toxicity, NASH and Leigh Syndrome.

    Abstract translation: 公开了青霉胺及其衍生物，组合物，合成和使用式1化合物的方法。 式1的化合物还包括其盐，多晶型物，溶剂合物和水合物。 这些化合物可以配制成药物组合物。 药物组合物可以根据口服，局部，经粘膜，吸入，靶向递送和缓释制剂配制。 这些组合物可用于治疗与铜毒性相关的肝和遗传疾病，NASH和Leigh综合征。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH
    10.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH 审中-公开
    组合物和治疗方法

    公开(公告)号：WO2013167988A1

    公开(公告)日：2013-11-14

    申请号：PCT/IB2013/050787

    申请日：2013-01-30

    Applicant: KANDULA, Mahesh

    Inventor： KANDULA, Mahesh

    IPC: C07D339/04 ,  C07C69/608 ,  C07C69/612 ,  C07C43/235 ,  A61K31/09 ,  A61K31/215 ,  A61K9/08 ,  A61P11/06 ,  A61P11/14 ,  A61P11/00 ,  A61P25/04 ,  A61P37/08

    CPC classification number: A61K47/48061 ,  A61K47/48038 ,  A61K47/542 ,  A61K47/545 ,  C07C43/23 ,  C07C323/59 ,  C07D339/04

    Abstract: The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promoies secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases.

    Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式（I）化合物的药物组合物，以及用于治疗或预防咳嗽的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这样的组合物可用于治疗急性呼吸道感染，哮喘，痛风，纤维肌痛，促进受孕，促进呼吸系统中的继发性粘膜分泌物，肌肉松弛剂，过敏，哮喘，慢性阻塞性肺病，痉挛，呼吸和神经疾病。

Patent Agency Ranking